MX355482B - Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. - Google Patents
Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.Info
- Publication number
- MX355482B MX355482B MX2014005996A MX2014005996A MX355482B MX 355482 B MX355482 B MX 355482B MX 2014005996 A MX2014005996 A MX 2014005996A MX 2014005996 A MX2014005996 A MX 2014005996A MX 355482 B MX355482 B MX 355482B
- Authority
- MX
- Mexico
- Prior art keywords
- adm
- antibody
- scaffold
- adrenomedullin
- fragment
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title abstract 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title abstract 6
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 102100026651 Pro-adrenomedullin Human genes 0.000 abstract 3
- 230000000087 stabilizing effect Effects 0.000 abstract 3
- 102000004379 Adrenomedullin Human genes 0.000 abstract 2
- 101800004616 Adrenomedullin Proteins 0.000 abstract 2
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
Abstract
La presente invención se refiere a un anticuerpo anti-adrenomedulina o un fragmento de anticuerpo anti-adrenomedulina o un andamio no lg anti-ADM, en donde dicho anticuerpo o dicho fragmento o andamio es un andamio no neutralizante, fragmento de anticuerpo o andamio no lg, respectivamente. La materia objeto de la presente invención también es un anticuerpo anti-adrenomedulina o un fragmento de anticuerpo anti-adrenomedulina o un andamio no lg anti-ADM para usarse en un tratamiento de una enfermedad crónica o aguda, en donde dicho anticuerpo o fragmento o andamio es: un anticuerpo de estabilización de ADM o un fragmento de anticuerpo de estabilización de adrenomedulina o un andamio no Ig de estabilización de ADM que mejora el tiempo de retención medio t1/2 de adrenomedulina en suero, sangre, plasma al menos 10%, preferiblemente al menos 50%, de mayor preferencia >50%, muy preferiblemente 100% y/o en donde dicho anticuerpo anti-ADM o un fragmento de anticuerpo anti-adrenomedulina o andamio no Ig anti-ADM bloquea la bioactividad de ADM a no más de 80%, o no más de 50%.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11189448 | 2011-11-16 | ||
| EP12160018 | 2012-03-16 | ||
| PCT/EP2012/072931 WO2013072512A1 (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005996A MX2014005996A (es) | 2015-03-09 |
| MX355482B true MX355482B (es) | 2018-04-19 |
Family
ID=48087103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005996A MX355482B (es) | 2011-11-16 | 2012-11-16 | Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2594588B1 (es) |
| JP (1) | JP6321545B2 (es) |
| KR (3) | KR102249078B1 (es) |
| CN (4) | CN118105479A (es) |
| AU (1) | AU2012338732B2 (es) |
| BR (2) | BR122019027917B1 (es) |
| CA (1) | CA2856141C (es) |
| DK (1) | DK2594588T3 (es) |
| ES (1) | ES2494191T3 (es) |
| HK (1) | HK1202127A1 (es) |
| IL (2) | IL283215B2 (es) |
| MX (1) | MX355482B (es) |
| PL (1) | PL2594588T3 (es) |
| PT (1) | PT2594588E (es) |
| RU (1) | RU2662671C2 (es) |
| SG (1) | SG11201402351WA (es) |
| WO (1) | WO2013072512A1 (es) |
| ZA (1) | ZA201403548B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102249078B1 (ko) * | 2011-11-16 | 2021-05-10 | 아드레노메드 아게 | 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드 |
| EP3380845A1 (en) * | 2015-11-27 | 2018-10-03 | B.R.A.H.M.S GmbH | MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT |
| SG11201900133WA (en) * | 2016-07-08 | 2019-02-27 | Sphingotec Gmbh | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| WO2018109228A1 (en) * | 2016-12-16 | 2018-06-21 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| WO2018181638A1 (ja) * | 2017-03-29 | 2018-10-04 | 国立大学法人宮崎大学 | 長時間作用型アドレノメデュリン誘導体 |
| WO2019057992A2 (en) * | 2017-09-25 | 2019-03-28 | Adrenomed Ag | ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE |
| WO2019077082A1 (en) | 2017-10-18 | 2019-04-25 | Adrenomed Ag | SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM) |
| KR20200135947A (ko) * | 2018-02-08 | 2020-12-04 | 스핑고텍 게엠베하 | 치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제 |
| CN114556100A (zh) | 2019-08-30 | 2022-05-27 | 4Teen4制药有限公司 | 用于治疗休克的疗法指引和/或疗法监测 |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| AU2021228207A1 (en) | 2020-02-27 | 2022-10-20 | 4TEEN4 Pharmaceuticals GmbH | DPP3 for therapy guidance, monitoring and stratification of nt-ADM antibodies in patients with shock |
| KR20220145897A (ko) | 2020-02-27 | 2022-10-31 | 아드레노메드 아게 | 쇼크의 치료 또는 예방에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드 |
| AU2021227279A1 (en) | 2020-02-27 | 2022-10-20 | Adrenomed Ag | Anti-adrenomedullin (ADM) binder for use in therapy of patients in shock |
| CN115917325A (zh) | 2020-03-16 | 2023-04-04 | 艾德里诺医药公司 | 感染冠状病毒的患者中的肾上腺髓质素原或其片段以及用针对肾上腺髓质素的结合剂进行的治疗 |
| WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| WO2024017331A1 (zh) * | 2022-07-20 | 2024-01-25 | 上海济煜医药科技有限公司 | 一种抗肾上腺髓质素非中和抗体、其制备方法及应用 |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (ja) * | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| PT1214600E (pt) * | 1999-09-10 | 2006-05-31 | Us Gov Health & Human Serv | Determinacao de proteinas de ligacao a adrenomedulina |
| BR0212256A (pt) | 2001-08-30 | 2004-08-31 | Biorexis Pharmaceutical Corp | Proteìnas de fusão de transferrina modificadas |
| CA2488558C (en) | 2002-06-07 | 2013-08-20 | Dyax Corp. | Prevention and reduction of blood loss |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| US20070082363A1 (en) | 2003-04-25 | 2007-04-12 | Lydie Bougueleret | Secreted polypeptide species reduced cardiovascular disorders |
| EP1675878A2 (en) | 2003-10-24 | 2006-07-05 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| WO2006027147A2 (en) | 2004-09-09 | 2006-03-16 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) |
| CA2477867A1 (en) * | 2004-09-17 | 2006-03-17 | Oncorex, Inc. | Peptides, dna's, rna's, and compounds for inhibiting or inducing adrenomedullin activity, and use of the same |
| CA2580881A1 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag | Use of microproteins as tryptase inhibitors |
| JP4976412B2 (ja) | 2005-12-01 | 2012-07-18 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法 |
| CN101165067B (zh) * | 2006-10-19 | 2011-04-20 | 四川大学华西医院 | 肾上腺髓质素(27-52)的固相合成方法 |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| KR101698362B1 (ko) | 2008-11-03 | 2017-01-20 | 몰리큘라 파트너스 아게 | Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질 |
| NZ598351A (en) | 2009-08-27 | 2014-08-29 | Covagen Ag | Il-17 binding compounds and medical uses thereof |
| BR112012014194A2 (pt) | 2009-12-14 | 2017-01-10 | Scil Proteins Gmbh | um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos |
| PL2580236T3 (pl) | 2010-06-08 | 2019-09-30 | Pieris Pharmaceuticals Gmbh | Muteiny lipokaliny łez wiążące IL-4 R alfa |
| KR102249078B1 (ko) * | 2011-11-16 | 2021-05-10 | 아드레노메드 아게 | 요법에 사용하기 위한 항-아드레노메둘린 (adm) 항체 또는 항-adm 항체 단편 또는 항-adm 비-ig 스캐폴드 |
-
2012
- 2012-11-16 KR KR1020207029323A patent/KR102249078B1/ko active IP Right Grant
- 2012-11-16 CN CN202410037251.0A patent/CN118105479A/zh active Pending
- 2012-11-16 ES ES12193121.6T patent/ES2494191T3/es active Active
- 2012-11-16 BR BR122019027917-9A patent/BR122019027917B1/pt active IP Right Grant
- 2012-11-16 DK DK12193121.6T patent/DK2594588T3/da active
- 2012-11-16 IL IL283215A patent/IL283215B2/en unknown
- 2012-11-16 PL PL12193121T patent/PL2594588T3/pl unknown
- 2012-11-16 CN CN201811275032.7A patent/CN110054690B/zh active Active
- 2012-11-16 EP EP12193121.6A patent/EP2594588B1/en active Active
- 2012-11-16 BR BR112014011670-9A patent/BR112014011670B1/pt active IP Right Grant
- 2012-11-16 AU AU2012338732A patent/AU2012338732B2/en active Active
- 2012-11-16 KR KR1020147015835A patent/KR102047443B1/ko active IP Right Grant
- 2012-11-16 SG SG11201402351WA patent/SG11201402351WA/en unknown
- 2012-11-16 CN CN201280066575.2A patent/CN104144948B/zh active Active
- 2012-11-16 MX MX2014005996A patent/MX355482B/es active IP Right Grant
- 2012-11-16 WO PCT/EP2012/072931 patent/WO2013072512A1/en active Application Filing
- 2012-11-16 KR KR1020197027994A patent/KR102176469B1/ko active IP Right Grant
- 2012-11-16 JP JP2014541696A patent/JP6321545B2/ja active Active
- 2012-11-16 PT PT121931216T patent/PT2594588E/pt unknown
- 2012-11-16 CN CN202111048028.9A patent/CN114044824A/zh active Pending
- 2012-11-16 CA CA2856141A patent/CA2856141C/en active Active
- 2012-11-16 RU RU2014123990A patent/RU2662671C2/ru active
-
2014
- 2014-05-14 IL IL232635A patent/IL232635B/en active IP Right Grant
- 2014-05-15 ZA ZA2014/03548A patent/ZA201403548B/en unknown
-
2015
- 2015-03-16 HK HK15102663.5A patent/HK1202127A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014005996A (es) | Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. | |
| MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| PH12019500440A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| PH12015502275B1 (en) | Therapuetic uses of empagliflozin | |
| WO2015054619A3 (en) | Use of a pcsk9 inhibitor to treat hyperlipidemia | |
| EA201490876A1 (ru) | Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| PH12018500641A1 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| IN2015DN00450A (es) | ||
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| EA201390335A1 (ru) | Введение лоркасерина индивидуумам с почечной недостаточностью | |
| MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
| MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
| EA200970816A1 (ru) | Новая лекарственная форма | |
| RU2012115039A (ru) | Способ лечения хронического эндометрита | |
| NZ624876A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation | |
| UA59444U (ru) | Способ выбора тактики гиполипидемической терапии женщин старше 50 лет с метаболическим синдромом | |
| RU2011128241A (ru) | Способ локальной терапии болевого синдрома при коксартрозе | |
| UA91048U (uk) | Спосіб лікування антифосфоліпідного синдрому | |
| UA112448C2 (uk) | Композиція і спосіб лікування аутоімунного захворювання | |
| RU2007140029A (ru) | Способ лечения хронической сердечной недостаточности |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |